Acorda Therapeutics announced that it has signed a new supply agreement with Catalent that reduces the amount of product that the company is required to buy annually from $18 million to $8.5 million for 2023 and $15.5 million for 2024. From 2025 on, the announcement says, Acorda will pay a fixed amount per capsule “based on the amount of Inbrija needed in the US and other markets.” The deal, which extends through 2030, also includes an $8 million payment to terminate the previous agreement.
The FDA approved Inbrija in December 2018 for the treatment of OFF episodes in Parkinson’s disease patients who take carbidopa/levodopa, and Acorda launched the DPI in the US in February 2019.
Catalent purchased the Inbrija manufacturing facility from Acorda in 2021 for $80 million in a deal that included the supply of Inbrija to Acorda. As part of the new agreement, Acorda will pay Catalent $1 million in 2023 and another $1 million in 2024 towards expansion of capacity at the plant, which is now known as Catalent’s Center of Excellence for Spray Dried Dispersions. The company said that the expansion “is expected to reduce per-capsule prices significantly.”
Acorda President and CEO Ron Cohen said, “This agreement ensures that people with Parkinson’s who benefit from Inbrija will have an uninterrupted supply of this important medication, and that it continues to be manufactured to the highest quality and safety standards. The agreement also will significantly reduce our cost of goods for Inbrija and, importantly, increase manufacturing capacity to ensure that we will be able to supply Inbrija to our commercial partners throughout the world, to meet expected increasing demand.”
Catalent’s Clinical Development and Supply Division President Ricky Hopson commented, “In addition to assuring the long-term supply of this prescription medicine to Parkinson’s patients who benefit from it, this new agreement will free much needed oral amorphous solid dispersion capacity at our Boston facility. As we expand our capabilities to include spray dry dispersion for bioavailability enhancement at the site, this freed capacity provides Catalent the opportunity to welcome new clients, both oral and dry-powders for inhalation, into our world class facility.”
Read the Acorda Therapeutics press release.
